Is cartilage preservation still possible in ankle OA?

For most patients presenting with post-traumatic ankle pain and early-to-mid stage radiographic changes, the answer is yes — cartilage preservation remains a realistic clinical goal, provided the joint has not yet crossed into end-stage degeneration.

The practical boundary is defined by the Takakura staging system. Stages 1 through 3B describe a spectrum of medial-compartment narrowing in which some joint space — and therefore some viable cartilage — remains. Stage 4, where bone meets bone across the joint, sits outside the preservation window. The majority of patients who come to clinic with ankle stiffness and activity-related pain after a fracture, ligament injury, or osteochondral lesion fall somewhere within Takakura 1–3B, which is precisely where preservation strategies are designed to work.

Viability within that window is not automatic, however. Three factors determine whether it is genuinely open for a given patient: how much residual cartilage stock remains, whether an underlying alignment problem can be corrected, and individual variables such as activity level and biological healing capacity. What follows examines each of these in turn — starting with why ankle OA behaves differently from knee or hip disease, and why that distinction matters for treatment planning.

Why ankle OA doesn't behave like knee OA

Ankle OA develops differently from the idiopathic wear most people associate with knee arthritis. The predominant driver is trauma — intra-articular fractures, ligamentous instability that loads cartilage unevenly over years, and osteochondral lesions that disrupt focal surface integrity. Roughly 12% of advanced OA across hips, knees, and ankles follows joint injury, with the ankle carrying the highest traumatic proportion of the three.

That origin changes the treatment logic. When the primary problem is mechanical malalignment rather than diffuse cartilage death, what remains is often biologically viable tissue being loaded incorrectly rather than consumed wholesale. At Takakura Stages 1–3B, the cartilage has been stressed into dysfunction — realignment and biological enhancement are therefore mechanistically sound, not merely theoretical. Stage 4, where bone-on-bone contact is complete, leaves no preservation target.

Idiopathic knee OA more commonly involves diffuse, symmetric surface loss across the joint, which limits the scope for focal correction. In the ankle, caught early, the architecture of the problem is often more tractable.

One further distinction: early-stage OA carries a more active inflammatory environment than end-stage disease — with higher concentrations of pro-inflammatory M1 macrophages — suggesting the joint may be more responsive to biological intervention at this phase than is commonly assumed.

How clinicians assess whether the window is still open

Determining residual cartilage viability requires more than a single plain film. Weight-bearing X-rays remain the primary staging tool — confirming which Takakura grade a patient sits in — but the more granular question is how much viable cartilage actually remains within that stage. Two emerging metrics address this directly.

CT Hounsfield unit (HU) measurement of talar subchondral bone provides a non-invasive surrogate for cartilage quality. HU values correlate strongly with histological Mankin scores (r = 0.756), and published cut-offs of 594 and 727 HU help discriminate mild from severe degeneration — offering practical, pre-operative information about whether the biological substrate for repair is still present.

For patients being considered specifically for supramalleolar osteotomy at Takakura 3B, the effective index of the talar dome articular surface (EITDAS) has emerged as a useful gating criterion. An EITDAS above 0.544 is associated with significantly better postoperative VAS, AOFAS, and SF-12 outcomes, suggesting that residual cartilage surface area must meet a minimum threshold for realignment to produce a meaningful benefit.

MRI adds complementary soft-tissue detail — cartilage signal, subchondral oedema, and synovial change — while direct arthroscopic assessment becomes relevant when X-ray and cross-sectional imaging leave staging ambiguous.

Both HU values and EITDAS are emerging biomarkers that inform clinical judgement rather than replace it; prospective validation remains ongoing. What they reveal shapes which intervention is appropriate — the two approaches the following sections cover.

Supramalleolar osteotomy: realignment as the primary preservation tool

The core logic of SMO is mechanical: by correcting varus malalignment at the tibial plafond, it shifts the joint's load-bearing axis away from the damaged medial compartment and onto cartilage that retains biological viability. This load redistribution does not replace cartilage — it removes the mechanical stress that is preventing recovery. Biologic repair becomes possible because the tissue itself still has that capacity, given the right conditions.

Evidence across Takakura Stages 2 and 3B bears this out. Studies of intermediate-stage varus ankle OA report statistically significant improvements in both VAS pain scores and AOFAS functional scores following SMO. Crucially, second-look arthroscopy in a subset of these patients has confirmed cartilage regeneration in the talar dome — not simply symptom relief or halted progression. Two variables consistently predict how well a patient does: the degree of talar dome cartilage regeneration achieved after surgery, and the extent of TAS angle correction — both independent predictors of final AOFAS outcome.

At Takakura 3B — the most advanced stage where preservation remains feasible — SMO is still viable, though patient selection matters more. An EITDAS above 0.544 is the practical preoperative threshold for likely benefit; those below it tend to see more modest gains. Where varus deformity is accompanied by significant talar tilt, fibular osteotomy using an oblique sliding technique can extend the correction achievable through the tibia alone.

The honest ceiling is that the supporting evidence, though consistent, comes from small-to-moderate surgical series rather than randomised controlled trials. SMO addresses alignment specifically — it does not directly target all the biological and inflammatory drivers present in early OA. Those mechanisms, and the interventions aimed at them, are the focus of the next section.

Distraction, biologics, and injectable scaffolds

Ankle distraction arthroplasty (ADA) operates on a different principle from SMO. Rather than correcting alignment, it unloads the joint intermittently using an external frame — most commonly an Ilizarov construct — allowing the cartilage surface a period of relative mechanical respite. MRI segmentation studies have documented this as a genuine regenerative effect: at 12 months, cartilage volume increased by approximately 247 mm³ at the talus and 272 mm³ at the tibia in patients treated with the Ilizarov frame. Combining ADA with arthroscopic microfracture at the time of frame application improves outcomes further — in one comparative series, the combined approach produced higher AOFAS scores (88.9 versus 85.0), better pain relief, and superior radiographic arthritis reduction compared with distraction alone.

At Takakura Stage 3, the direct comparison with SMO produces a clinically useful distinction. Both techniques achieve comparable VAS and AOFAS improvements at approximately 32 months. Where they differ is in what each does best: distraction tends to preserve range of motion more effectively across all planes, while SMO provides more reliable correction of varus malalignment. That difference, rather than a simple hierarchy, should guide selection — a patient with significant deformity and minimal ROM loss is typically a better candidate for SMO; one whose primary concern is stiffness and mechanical load may do better with distraction.

Biological and injectable adjuncts

Biological options sit alongside these mechanical strategies rather than replacing them. Autologous matrix-induced chondrogenesis (AMIC) has the most mature cartilage-specific evidence for focal talar defects, with systematic review data supporting benefit out to eight years. BMAC may enhance repair, particularly when used alongside other surgical techniques, but supporting evidence remains largely Level II–IV and no high-quality RCT has established its independent efficacy. PRP combined with hyaluronic acid showed meaningful VAS reduction in a 15-patient ankle-specific cohort, but the absence of a control arm limits what can be concluded.

For focal residual defects within the preservation window, injectable collagen scaffolds represent a further biological category. These acellular matrix devices are designed to recruit the patient's own progenitor cells and support matrix-induced chondrogenesis within the defect; as an ultrasound-guided outpatient procedure, they carry a different recovery profile from theatre-based cartilage repair. The evidence base for this modality in the ankle is still developing, and suitability depends on the size and location of the defect and the degree of surrounding cartilage viability — criteria best evaluated at specialist assessment.

Getting assessed while the window is still open

The evidence across the preceding sections points to a consistent conclusion: early-to-mid stage ankle OA — particularly the post-traumatic, varus-driven variety that characterises most cases at Takakura Stages 2 and 3B — is amenable to preservation, but the biology is conditional. EITDAS thresholds, CT Hounsfield values, and Takakura staging all converge on the same limiting variable: residual cartilage stock. That stock depletes with continued abnormal loading, and Stage 3B can progress to Stage 4. At Stage 4, the mechanical and biological rationale for preservation collapses entirely.

Watchful waiting without structural assessment is therefore not a neutral choice. For patients with persistent ankle pain following trauma, ligamentous instability, or a known osteochondral lesion who have not yet reached bone-on-bone contact, the clinically appropriate step is specialist assessment — weight-bearing imaging, Takakura staging, and a discussion of which interventions match the alignment pattern and remaining cartilage stock — rather than continued expectant management.

For patients in London and the commuter belt where focal cartilage pathology sits within that window, the ChondroFiller injection — an ultrasound-guided outpatient collagen scaffold — represents one biological option within this pathway, available at the London Cartilage Clinic on Harley Street under Professor Paul Y. F. Lee. Further information is at londoncartilage.com.

1. [1] The Hounsfield Unit Values of Talar Subchondral Bone Predict Articular Cartilage Degeneration in Patients With Ankle Osteoarthritis. (2024). https://doi.org/10.1177/10711007241268111 https://doi.org/10.1177/10711007241268111
2. [2] Clinical Outcomes of Supramalleolar Osteotomy in Intermediate Stage of Varus Ankle Osteoarthritis in Joint Preservation. (2022). https://doi.org/10.1053/j.jfas.2022.04.002 https://doi.org/10.1053/j.jfas.2022.04.002
3. [3] Effective Index of Talar Dome Articular Surface as a Predictor of Clinical Outcomes for Supramalleolar Osteotomy for Takakura 3B Ankle Osteoarthritis. (2025). https://doi.org/10.1177/2473011425s00230 https://doi.org/10.1177/2473011425s00230
4. [4] Joint Preservation Strategies for Managing Varus Ankle Deformities. (2022). https://doi.org/10.1016/j.fcl.2021.11.002 https://doi.org/10.1016/j.fcl.2021.11.002
5. [5] Clinical Outcomes of Ankle Distraction Arthroplasty Versus Supramalleolar Osteotomy for Treatment of Post-Traumatic Ankle Arthritis. (2022). https://doi.org/10.21203/rs.3.rs-1140232/v1 https://doi.org/10.21203/rs.3.rs-1140232/v1
6. [6] Clinical Outcomes of Ankle Distraction Arthroplasty Versus Supramalleolar Osteotomy for Treatment of Post-traumatic Ankle Arthritis in Young Adult Patients. (2022). https://doi.org/10.21203/rs.3.rs-1330171/v1 https://doi.org/10.21203/rs.3.rs-1330171/v1
7. [7] OBSERVATIONAL STUDY ON PRP THERAPY FOR KNEE AND ANKLE OSTEOARTHRITIS: CLINICAL INSIGHTS. (2024). https://doi.org/10.36106/ijsr/0608161 https://doi.org/10.36106/ijsr/0608161
8. [8] Neuropeptide-Mediated Crosstalk between Subchondral Bone and Articular Cartilage in Ankle Osteoarthritis: A Cross-Sectional Histologic Study of 17 Ankles. (2025). https://doi.org/10.1177/10711007251372141 https://doi.org/10.1177/10711007251372141